A prospective multi-site registry study of a specific protocol of autologous bone marrow concentrate for the treatment of shoulder rotator cuff tears and osteoarthritis

• DOI: 10.2147/jpr.s80872
• Publication Date: 2015-06-07T19:56:17Z
• Authors: Jamil Bashir; Christopher Centeno; Michael Freeman; Hasan Al-Sayegh; Shaun Goodyear
• Keywords: 2. Zero hunger; Medicine (General); 03 medical and health sciences; R5-920; 0302 clinical medicine; 13. Climate action; Journal of Pain Research; Original Research; 3. Good health

Shoulder pain is a common musculoskeletal complaint in the general population. Bone marrow concentrate (BMC) injections offer promising potential as minimally invasive approach for treatment of shoulder degenerative disease. In this study, we investigated clinical outcomes BMC and disability due to osteoarthritis (OA) rotator cuff tears registry population.A total 115 shoulders 102 patients were treated with autologous symptomatic OA at glenohumeral joint and/or tears. Data collected factors potentially influencing outcome, including age, sex, body mass index, type condition (ie, or tear). Clinical assessed serially over time using disabilities arm, hand score (DASH), numeric scale (NPS), subjective improvement rating scale. Baseline scores compared most recent outcome analysis adjusted demographic differences. We reported comparisons pre- post-treatment scores, differences between groups, predictive effects on outcomes.At current follow-up assessment after treatment, average DASH decreased (improved) from 36.1 17.1 (P<0.001) value 4.3 2.4 (P<0.001). These changes associated an 48.8%. No observed among versus tears, nor did index influence functional outcomes. There no significant treatment-related adverse events reported.We preliminarily encouraging results following serve basis design adequately powered randomized controlled trial.